Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.

Oncotarget - 4 Jul 2017

Lu Wei-Qun, Hu Ying-Ying, Lin Xiao-Ping, Fan Wei

Abstract excerpt

Clinical treatment for colorectal cancer (CRC) thus far encounters a huge challenge due to oxaliplatin-resistance. As crucial rate-limiting enzymes in aerobic glycolysis and glutaminolysis, pyruvate kinase M2 type (PKM2) and kidney-type glutaminase (GLS1) are proposed to carry important implications in colorectal carcinogenesis and drug-resistance. This study aimed to explore the possible association of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Gene Knockdown Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutaminase

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Thyroid Hormones

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28498807
DOI: 10.18632/oncotarget.17396
PMCID: PMC5546471

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.PMID 28498807Read ↗

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell LinesSemantic proximity Read ↗

A pan-cancer analysis of the glutaminase and their association with prognosis, tumor microenvironment, and therapeutic targetsSemantic proximity Read ↗

TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approachSemantic proximity Read ↗

Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancerSemantic proximity Read ↗

The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.Semantic proximity Read ↗

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal CancerSemantic proximity Read ↗

Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacitySemantic proximity Read ↗

Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell linesSemantic proximity Read ↗

A novel lncRNA 495810 promotes the aerobic glycolysis in colorectal cancer by stabilizing pyruvate kinase isozyme M2Semantic proximity Read ↗

Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic CancerSemantic proximity Read ↗

Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasisSemantic proximity Read ↗

ENO3 promotes colorectal cancer progression by enhancing cell glycolysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.